Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TELA Bio (TELA) EBITDA Margin (2018 - 2026)

TELA Bio has reported EBITDA Margin over the past 8 years, most recently at 43.32% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 918.0% year-over-year to 43.32%; the TTM value through Dec 2025 reached 48.37%, up 623.0%, while the annual FY2025 figure was 48.37%, 623.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 43.32% at TELA Bio, down from 41.59% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 34.06% in Q1 2024 and troughed at 123.69% in Q1 2021.
  • A 5-year average of 76.45% and a median of 77.19% in 2024 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: surged 6936bps in 2021 and later crashed -2676bps in 2025.
  • Year by year, EBITDA Margin stood at 91.4% in 2021, then increased by 11bps to 81.22% in 2022, then increased by 6bps to 76.09% in 2023, then skyrocketed by 31bps to 52.51% in 2024, then grew by 17bps to 43.32% in 2025.
  • Business Quant data shows EBITDA Margin for TELA at 43.32% in Q4 2025, 41.59% in Q3 2025, and 49.12% in Q2 2025.